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In the course of human medicine, few discoveries have been as far-reaching and successful as the 
development of antibiotics in the 20th century. 
Introduced to mainstream medicine in the 1940s, 
these drugs have been utilized to vanquish a vast 
array of bacterial infections, relieving the suffering 
and saving the lives of millions of people. But 
antibiotics aren’t the surefire defense they used 
to be. A drop in research over the past several 
decades in developing new antibiotics, coupled with 
bacteria’s evolutionary drive to develop resistance, 
has caused the number of effective antibiotics to 
diminish, and with increasing speed. 
Christine Chow, Ph.D., professor of Chemistry in 
Wayne State’s College of Liberal Arts and Sciences, 
is leading a research team in developing a novel 
strategy to get an edge over bacteria’s relentlessly 
evolving defense mechanisms. “Resistance is a huge 
problem,” Dr. Chow said. “There are now strains 
of bacteria that are completely resistant to every 
known drug. We want to create something new that 
isn’t as easy for bacteria to resist.” 
The key to Dr. Chow’s research lies in ribonucleic 
acid, or RNA, a nucleic acid that consists of a long 
chain of nucleotide units, chemically similar to 
DNA, but consisting of one chain of nucleotides 
instead of DNA’s double helix. RNA has a diverse 
set of functions, but one of the basic and most well-
known is its job of containing the genetic “recipe” 
for synthesizing proteins. RNA’s role has been 
highly conserved throughout evolution – organisms 
from bacteria all the way to humans depend on its 
functions. 
Being such an important aspect of all life 
also makes RNA an incredibly useful target for 
antibiotics. The RNA of bacteria is one of the two 
most common targets for antibiotics – the other 
being enzymes that synthesize bacteria’s cell walls – 
for several reasons, Dr. Chow explained. First, RNA 
is more chemically and structurally diverse than 
other possible target areas, such as DNA, meaning 
RNA has an abundance of unique structures for an 
antibiotic to “latch on to.” It’s also more accessible 
than DNA, and doesn’t have the defense enzymes 
that protect DNA. Lastly, RNA comprises the 
physical structure of the ribosome, RNA-protein 
complexes that are found in all living organisms. 
Ribosomes perform the essential function of 
synthesizing all the proteins in an organism. Like 
RNA itself, these protein-making machines can be 
found from bacteria all the way up to humans, and 
are important to maintaining all life. Because of this 
importance, ribosomes are already one of the most 
common targets of antibiotics – one of simplest 
ways to eliminate unwanted bacteria is to shut 
down its ribosomes.
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Chow’s strategy for battling antibiotic resistance 
takes the tried and true method of targeting a 
bacteria cell’s ribosomes and aims to improve it, by 
targeting sites that are particularly vulnerable and 
attacking with a compound the bacteria has never 
seen before. “If your antibiotics are derived from 
natural compounds, there has already been time 
for the bacteria to evolve resistance mechanisms, 
and that’s why we have this big problem with 
antibiotic resistance,” she said. “So we want to find 
compounds that don’t look like anything from 
nature. That way, resistance mechanisms 
will hopefully take longer to develop.”
Selecting a target
Just like DNA, RNA’s “genetic code” is 
subject to modifications – changes in either 
its chemical make-up or structure that enable it to 
carry out vital functions. With her lab, Chow has 
selected regions of RNA with six different natural 
modifications as potential antibiotic targets. Chosen 
for their importance to ribosome function, Chow’s 
lab is synthesizing these modified portions of RNA, 
using miniaturized versions of the full scale RNAs so 
that individual nucleotides can be monitored more 
closely. All six modified portions of RNA are located 
at different places on the physical structure of the 
ribosome, and are believed to control such vital 
processes as the maintenance of protein assembly 
and control of turning protein synthesis on and off. 
“We wanted to target areas that are very essential 
for the survival of cells,” she said. 
Finding the weapon
With the targets of the “protein machine” 
chosen, Chow’s task at hand is finding a chemical 
“monkey wrench” that will bind to a ribosome 
and shut down its protein production. The process 
will involve several steps, beginning with finding 
a compound that has an affinity for one of the 
modified sites, and will bind to it. “If there is a 
strong interaction, that means the compound has 
potential to be a drug,” Dr. Chow said. “The next 
step is to look and see if it affects the ribosome 
function. In other words, does it stop protein 
synthesis? If that does happen, that’s great, but 
there is still another question, which is, can this 
compound get into cells? If the drug never gets 
into the cells, then it can’t kill them.” 
To find additional information on the nature of 
bacterial RNA, Chow is also performing these trials 
on the corresponding modified RNA sites in human 
ribosomes, looking for any functional or structural 
differences that will further her understanding of 
bacterial RNA at these modified sites. “We want to 
know if the function of these modifications is the 
same in both organisms” she said. “We believe that 
even though the modifications occur in both, they 
might have slightly different roles or effects on the 
RNA. And what we really want to do is determine 
the differences so that we can take advantage of 
them for drug targeting.”
Even with the advantage of brand new chemical 
compounds, however, Chow knows that bacteria 
may still develop resistance to the antibiotics 
she develops. She is collaborating with Phil 
Cunningham, Ph.D., associate professor of biology 
in WSU’s College of Liberal Arts and Sciences, to 
utilize the genetic system Cunningham developed 
that predicts “functional mutants” – the potential 
mutations bacterial RNAs are likely to take on. 
“We’re trying to do a screening to find compounds 
that bind to functional mutants, so once the 
bacteria develops a mutation to an antibiotic, we’ll 
already have a drug ready,” she said. 
In the meantime, Chow is hard at work looking 
for a drug that will be a new challenge for bacteria 
to defend against. “Our hope is to find a lead 
compound, something that could potentially lead 
to an antibiotic,” she said. “If not, we’ll at least 
learn a lot about the rules for how compounds bind 
and that would help other people to design  
new drugs.”
About Dr. Christine Chow:  Dr. Chow received an A.B. 
in environmental studies and chemistry from Bowdoin College 
and an M.A. in organic chemistry from Columbia University. She 
studied inorganic chemistry with a focus on the interactions 
of transition metal complexes with RNA at the California 
Institute of Technology, where she earned a Ph.D. She then 
became a National Institutes of Health postdoctoral fellow 
at the Massachusetts Institute of Technology, studying the 
interactions of proteins with DNA modified by the anticancer 
drug Cisplatin. She joined Wayne State University in 1994. 
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